---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-050951"
form_type: "8-K"
ticker: "CERO"
cik: "0001870404"
company_name: "CERO THERAPEUTICS HOLDINGS, INC."
filed_at: "2026-05-01T23:59:59+00:00"
generated_at: "2026-05-15T00:22:24.439782+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CERo Therapeutics issues $500K convertible note to Keystone Capital at 10% interest

## Summary
- Initial purchase price $400,000; principal face value $500,000; up to $1M aggregate available.
- Note matures April 27, 2027; bears 10% annual interest; convertible at lower of $0.05 or 80% of 5 lowest intraday prices in prior 20 days.
- Conversion subject to 4.99% beneficial ownership limitation; resale registration required on Form S-1 or S-3.
- Issuance exempt under Section 4(a)(2) and Rule 506(b); accredited investor only.

## SEC filing metadata
- accession: 0001213900-26-050951
- form_type: 8-K
- ticker: CERO
- cik: 0001870404
- company_name: CERO THERAPEUTICS HOLDINGS, INC.
- filed_at: 2026-05-01T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1870404/000121390026050951/0001213900-26-050951-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1870404/000121390026050951/ea028870101-8k_cero.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-050951
- JSON: https://secwatch.observer/filing/0001213900-26-050951.json
- Plain text: https://secwatch.observer/filing/0001213900-26-050951.txt

## Key facts
- Debt Financings
  CERO THERAPEUTICS HOLDINGS, INC. incurred convertible notes of $400,000, having a principal face value of $500,000 with Keystone Capital Partners, LLC at 10% per annum maturing April 27, 2027.
  - Instrument: convertible notes
  - Principal: $400,000, having a principal face value of $500,000
  - Counterparty: Keystone Capital Partners, LLC
  - Rate: 10% per annum
  - Maturity: April 27, 2027
  - Event: incurrence
  source text: On April 27, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the "Company") issued and sold a convertible promissory note for an purchase price of $400,000, having a principal face value of $500,000 (the "Note") to Keystone Capital Partners, LLC ("Lender").
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870404/000121390026050951/0001213900-26-050951-index.htm
- Equity Issuances
  CERO THERAPEUTICS HOLDINGS, INC. issued convertible note to Keystone Capital Partners, LLC for $400,000.
  - Security: convertible note
  - Purchaser: Keystone Capital Partners, LLC
  - Consideration: $400,000
  source text: On April 27, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for an purchase price of $400,000, having a principal face value of $500,000 (the “Note”) to Keystone Capital Partners, LLC (“Lender”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870404/000121390026050951/0001213900-26-050951-index.htm
- Material Agreements
  CERO THERAPEUTICS HOLDINGS, INC. entered into Note with Keystone Capital Partners, LLC valued at $400,000 (effective 2026-04-27).
  - Action: entry
  - Agreement: notes offering
  - Counterparty: Keystone Capital Partners, LLC
  - Value: $400,000
  - Effective: 2026-04-27
  source text: On April 27, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for an purchase price of $400,000, having a principal face value of $500,000 (the “Note”) to Keystone Capital Partners, LLC (“Lender”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870404/000121390026050951/0001213900-26-050951-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.